Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes

European Journal of Cancer

Volumn 84, Issue , 2017, Pages 69-80

  Stintzing, Sebastian ^a   Tejpar, Sabine ^b   Gibbs, Peter ^c   Thiebach, Lars ^d   Lenz, Heinz Josef ^e  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d ROCHE INNOVATION CENTER MUNICH   (Germany)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Colon; Colorectal carcinoma; Hindgut; Metastatic; Midgut; Predictive; Prognostic

Indexed keywords

CANCER PROGNOSIS; CANCER THERAPY; CHROMOSOME ANALYSIS; CLINICAL ASSESSMENT; CLINICAL OUTCOME; COLORECTAL CANCER; DISEASE ASSOCIATION; EMBRYOLOGY; HUMAN; INTESTINE; META ANALYSIS (TOPIC); MICROBIOME; MIDGUT; MOLECULAR BIOLOGY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THERAPY EFFECT; TUMOR LOCALIZATION; ANTAGONISTS AND INHIBITORS; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; ENZYMOLOGY; GENETICS; INTESTINE FLORA; METABOLISM; METASTASIS; MOLECULAR DIAGNOSIS; MUTATION; PATHOLOGY; PERSONALIZED MEDICINE; PREDICTIVE VALUE; RECTAL NEOPLASMS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; GASTROINTESTINAL MICROBIOME; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; NEOPLASM METASTASIS; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 85026781750     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.07.016     Document Type: Review

References (51)

1. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:5 (2015), E359–E386.
2. Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J.W., Comber, H., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:6 (2013), 1374–1403.
3. Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:8 (2016), 1386–1422.
4. Bufill, J.A., Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 113:10 (1990), 779–788.
5. Gervaz, P., Bucher, P., Morel, P., Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol 88:4 (2004), 261–266.
6. Iacopetta, B., Are there two sides to colorectal cancer?. Int J Cancer 101:5 (2002), 403–408.
7. Hemminki, K., Santi, I., Weires, M., Thomsen, H., Sundquist, J., Bermejo, J.L., Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes. BMC Cancer, 10, 2010, 688.
8. Loupakis, F., Yang, D., Yau, L., Feng, S., Cremolini, C., Zhang, W., et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst, 107(3), 2015.
9. Nitsche, U., Stogbauer, F., Spath, C., Haller, B., Wilhelm, D., Friess, H., et al. Right sided colon cancer as a distinct histopathological subtype with reduced prognosis. Dig Surg 33:2 (2016), 157–163.
10. Price, T.J., Beeke, C., Ullah, S., Padbury, R., Maddern, G., Roder, D., et al. Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?. Cancer 121:6 (2015), 830–835.
11. Sinicrope, F.A., Mahoney, M.R., Yoon, H.H., Smyrk, T.C., Thibodeau, S.N., Goldberg, R.M., et al. Analysis of molecular markers by anatomic tumor site in stage III colon carcinomas from adjuvant chemotherapy trial NCCTG N0147 (alliance). Clin Cancer Res 21:23 (2015), 5294–5304.
12. Venook, A., Niedzwiecki, D., Innocenti, F., Fruth, B., Greene, C., O'Neil, B., et al. Impact of primary (1º) tumor location on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol, 34(Suppl.; abstr 3504), 2016.
13. Wong, H.L., Lee, B., Field, K., Lomax, A., Tacey, M., Shapiro, J., et al. Impact of primary tumor site on bevacizumab efficacy in metastatic colorectal cancer. Clin Colorectal Cancer 15:2 (2016), e9–e15.
14. Boeckx, N., Toler, A., Op de Beeck, K., Kafatos, G., Deschoolmeester, V., Rolfo, C., et al. Primary tumor sidedness impacts on prognosis and treatment outcome: results from three randomized studies of panitumumab plus chemotherapy versus chemotherapy or chemotherapy plus bevacizumab in 1st and 2nd line RAS/BRAF WT mCRC. Ann Oncol 27:Suppl. 6 (2016), vi15–vi42.
15. Modest, D.P., Schulz, C., von Weikersthal, L.F., Quietzsch, D., von Einem, J.C., Schalhorn, A., et al. Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment). Anticancer Drugs 25:2 (2014), 212–218.
16. Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol, 2016 Oct 10, 10.1001/jamaoncol.2016.3797 [Epub ahead of print].
17. Wang, F., Bai, L., Liu, T.S., Yu, Y.Y., He, M.M., Liu, K.Y., et al. Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab. Chin J Cancer 34:9 (2015), 384–393.
18. Hill, M.A., Embryology gastrointestinal tract development. 2016.
19. Sadler, T.W., Langman's medical embryology. 2014.
20. Guinney, J., Dienstmann, R., Wang, X., de Reynies, A., Schlicker, A., Soneson, C., et al. The consensus molecular subtypes of colorectal cancer. Nat Med 21:11 (2015), 1350–1356.
21. Kawazoe, Y., Sekimoto, T., Araki, M., Takagi, K., Araki, K., Yamamura, K., Region-specific gastrointestinal Hox code during murine embryonal gut development. Dev Growth Differ 44:1 (2002), 77–84.
22. Missiaglia, E., Jacobs, B., D'Ario, G., Di Narzo, A.F., Soneson, C., Budinska, E., et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 25:10 (2014), 1995–2001.
23. Gao, Z., Guo, B., Gao, R., Zhu, Q., Qin, H., Microbiota disbiosis is associated with colorectal cancer. Front Microbiol, 6, 2015, 20.
24. Kohoutova, D., Smajs, D., Moravkova, P., Cyrany, J., Moravkova, M., Forstlova, M., et al. Escherichia coli strains of phylogenetic group B2 and D and bacteriocin production are associated with advanced colorectal neoplasia. BMC Infect Dis, 14, 2014, 733.
25. Zhang, Y., Hoffmeister, M., Weck, M.N., Chang-Claude, J., Brenner, H., Helicobacter pylori infection and colorectal cancer risk: evidence from a large population-based case-control study in Germany. Am J Epidemiol 175:5 (2012), 441–450.
26. Ahn, J., Sinha, R., Pei, Z., Dominianni, C., Wu, J., Shi, J., et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst 105:24 (2013), 1907–1911.
27. Dejea, C.M., Wick, E.C., Hechenbleikner, E.M., White, J.R., Mark Welch, J.L., Rossetti, B.J., et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci USA 111:51 (2014), 18321–18326.
28. Flemer, B., Lynch, D.B., Brown, J.M., Jeffery, I.B., Ryan, F.J., Claesson, M.J., et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut 66:4 (2017), 633–643.
29. Weiss, J.M., Pfau, P.R., O'Connor, E.S., King, J., LoConte, N., Kennedy, G., et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results–medicare data. J Clin Oncol 29:33 (2011), 4401–4409.
30. Shen, H., Yang, J., Huang, Q., Jiang, M.J., Tan, Y.N., Fu, J.F., et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol 21:21 (2015), 6470–6478.
31. Lan, Y.T., Jen-Kou, L., Lin, C.H., Yang, S.H., Lin, C.C., Wang, H.S., et al. Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers. J Surg Oncol 111:7 (2015), 905–910.
32. Yamauchi, M., Morikawa, T., Kuchiba, A., Imamura, Y., Qian, Z.R., Nishihara, R., et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 61:6 (2012), 847–854.
33. Mouradov, D., Sloggett, C., Jorissen, R.N., Love, C.G., Li, S., Burgess, A.W., et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res 74:12 (2014), 3238–3247.
34. Rowan, A., Halford, S., Gaasenbeek, M., Kemp, Z., Sieber, O., Volikos, E., et al. Refining molecular analysis in the pathways of colorectal carcinogenesis. Clin Gastroenterol Hepatol 3:11 (2005), 1115–1123.
35. Lee, M.S., McGuffey, E.J., Morris, J.S., Manyam, G., Baladandayuthapani, V., Wei, W., et al. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. Br J Cancer 114:12 (2016), 1352–1361.
36. Mayer, B., Zoller, M., Singer, T., Magosch, S., Joka, M., Werner, J., Targeted therapy using trastuzumab will overcome chemotherapeutic failure in liver metastasis of colorectal cancer. Eur Surg Res, 2015.
37. Lee MSA, S.M., Morris, J., Jiang, Z.-Q., Manyam, G.C., Menter, D., Broom, B.M., et al. Association of primary (1°) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (αEGFR) therapy. J Clin Oncol, 34, 2016.
38. Bendardaf, R., Buhmeida, A., Hilska, M., Laato, M., Syrjanen, S., Syrjanen, K., et al. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res 28:6B (2008), 3865–3870.
39. Nasir, A., Kaiser, H.E., Boulware, D., Hakam, A., Zhao, H., Yeatman, T., et al. Cyclooxygenase-2 expression in right- and left-sided colon cancer: a rationale for optimization of cyclooxygenase-2 inhibitor therapy. Clin Colorectal Cancer 3:4 (2004), 243–247.
40. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Colon cancer. 2017 https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
41. Petrelli, F., Tomasello, G., Borgonovo, K., Ghidini, M., Turati, L., Dallera, P., et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol, 2016.
42. von Einem, J.C., Heinemann, V., von Weikersthal, L.F., Vehling-Kaiser, U., Stauch, M., Hass, H.G., et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol 140:9 (2014), 1607–1614.
43. Matsusaka, S., Hanna, D.L., Cao, S., Zhang, W., Yang, D., Ning, Y., et al. Prognostic impact of IL6 genetic variants in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. Clin Cancer Res 22:13 (2016), 3218–3226.
44. Modest, D.P., Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehlong-Kaiser, U., et al. Primary tumor location and efficacy of second-line therapy after initial treatment with FOLFIRI in combination with cetuximab or bevacizumab in patients with metastatic colorectal cancer- FIRE-3 (AIOKRK0306). J Clin Oncol, 35(Suppl.), 2017.
45. Holch, J.W., Ricard, I., Stintzing, S., Modest, D.P., Heinemann, V., The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer 70 (2017), 87–98.
46. Houts, A.C., Ogale, S., Sommer, N., Walker, M.S., Treatment patterns and outcomes in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC) treated in first line with bevacizumab (B) or cetuximab (C) containing regimens. J Clin Oncol, 34, 2016.
47. Lenz, H., Lee, F., Yau, L., Koh, H., Knost, K., Mitchell, E., et al. MAVERICC, a phase 2 study of mFOLFOX6bevacizumab (BV) vs FOLFIRIBV with biomarker stratification as firstline (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol, 34(Suppl. 4S; abstr 493), 2016.
48. Brule, S.Y., Jonker, D.J., Karapetis, C.S., O'Callaghan, C.J., Moore, M.J., Wong, R., et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer 51:11 (2015), 1405–1414.
49. Raghav, K.P.S., Overman, Micheal J., Yu, R., Meric-Bernstam, F., Menter, D., Kee, B.K., et al. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol, 34, 2016.
50. Sugai, T., Habano, W., Nakamura, S., Sato, H., Uesugi, N., Takahashi, H., et al. Genetic alterations in DNA diploid, aneuploid and multiploid colorectal carcinomas identified by the crypt isolation technique. Int J Cancer 88:4 (2000), 614–619.
51. Lu, H.J., Lin, J.K., Chen, W.S., Jiang, J.K., Yang, S.H., Lan, Y.T., et al. Primary tumor location is an important predictive factor for wild-type KRAS metastatic colon cancer treated with cetuximab as front-line bio-therapy. Asia Pac J Clin Oncol 12:3 (2016), 207–215.